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General Hospital, University of California, San Francisco, CaliforniaABSTRACT Mechanisms for meconium-induced inactivation of pulmonary surfactant as part of the meconium aspiration
syndrome in newborn infants, to our knowledge, are not clearly understood. Here we have studied the biophysical mechanisms
of how meconium affects surface activity of pulmonary surfactant and whether the membrane-perturbing effects of meconium
can be mimicked by exposure of surfactant to a mixture of bile acids and cholesterol. Surface activity of pulmonary surfactant
complexes purified from animal lungs was analyzed in the absence and in the presence of meconium in standard surface
balances and in a captive bubble surfactometer. We have also evaluated accumulation of surfactant at the air-liquid interface
by what we believe to be a novel microtiter plate fluorescent assay, and the effect of meconium components on surfactant
membrane fluidity using Laurdan fluorescence thermotropic profiles and differential scanning calorimetry thermograms. Rapid
interfacial adsorption, low surface tension upon film compression, efficient film replenishment upon expansion, and thermotropic
properties of surfactant complexes are all adversely affected bymeconium, and, in a similar manner, they are affected by choles-
terol/taurocholate mixtures but not by taurocholate alone. We conclude that inhibition of surfactant by meconium can be
mimicked by a bile salt-promoted incorporation of excess cholesterol into surfactant complexes. These results highlight the
potential pathogenic role of cholesterol-mobilizing agents as a crucial factor resulting in cholesterol induced alterations of struc-
ture and dynamics of surfactant membranes and films.INTRODUCTIONPulmonary surfactant is a complex mixture of lipids and
proteins lining the alveolar air-water interface. By lowering
the surface tension, pulmonary surfactant stabilizes the
respiratory surfaces against physical forces tending to
collapse the air spaces (1,2). Lack or alteration of surfactant
is associated with severe respiratory pathologies in neonates
and adults (1–3). Premature newborn infants suffering from
respiratory distress syndrome now receive treatment with
clinical surfactants as the standard of care.
Meconium aspiration syndrome (MAS) remains an im-
portant cause of morbidity and mortality affecting >20,000
neonates per year in United States. MAS is characterized
by airway obstruction, pneumonitis, pulmonary hyperten-
sion, ventilation/perfusion mismatch, acidosis, and hypox-
emia (2). There is also underlying surfactant inactivation
but the mechanisms are still not well understood. In
controlled trials, some benefit has been shownwith surfactant
treatment, but the effect is less dramatic than the use of
surfactant for premature infants with respiratory distress
syndrome (4).
Meconium is a complex mixture that accumulates in the
fetal gut during gestation. It contains proteins, sterols, bile
salts, and inorganic molecules. The main sterol is choles-
terol and bile salts include cholic acid, taurocholic acid,
and glycocholic acid (5–7). It is normally excreted as the
first stool of a newborn baby during the first hours of life.Submitted August 4, 2010, and accepted for publication December 16, 2010.
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0006-3495/11/02/0646/10 $2.00In ~1–2% of deliveries, the fetus has aspirated meconium-
laden amniotic fluid, and as a newborn, manifests meconium
aspiration pneumonia, one aspect of which is inactivation of
alveolar surfactant. Presumably better understanding of the
nature of surfactant inactivation may lead to better treat-
ments of this condition.
At least two different mechanisms have been proposed for
surfactant inactivation after lung injuries causing respiratory
distress (8,9). A first model involves blood proteins, inflam-
mation proteins and other surface-active substances, which
compete with surfactant complexes for reaching the inter-
face (10). A second model hypothesizes that surfactant
dysfunction results from the intrinsic impairment of surfac-
tant complexes by small amphiphilic molecules such as free
fatty acids, cholesterol, lysolipids, bile acids, and/or diacyl-
glycerol. These substances, in part coming from the degra-
dation of surfactant itself by inflammatory phospholipases,
insert into the surfactant complexes rendering it dysfunc-
tional (11).
In this article, we have characterized the inhibition of
pulmonary surfactant by meconium using different biophys-
ical techniques. We propose that inhibition of surfactant is
produced by transfer of some components like cholesterol
from meconium into surfactant complexes, facilitated by
bile salts. To confirm this inhibitory mechanism, we have
compared the effect of the exposure of surfactant to meco-
nium with the effects of its exposure to a mixture of bile
salts and cholesterol.doi: 10.1016/j.bpj.2010.12.3715
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Materials
Native porcine lung surfactant was purified from bronchoalveolar lavage as
previously described (12). Isolated surfactant was used without further
organic extraction, in aqueous solution, and contains full complement of
proteins SP-A, SP-B, and SP-C. It also maintains most of its original struc-
ture as routinely checked by electron microscopy (13). Surfactant concen-
tration was measured by analysis of lipid phosphorus (14). Dilutions of the
material to the required phospholipid concentration were made with 5 mM
Tris buffer, pH 7, containing 150 mM NaCl. Incubation of native surfactant
and meconium at the desired concentration was carried out before testing.
The organic extract of meconium was obtained following the standard
Bligh & Dyer method. First-passed meconium from term infants was
collected and lyophilized as a pool. Dry weight of meconium was used in
mixtures with surfactant. BODIPY-PC or Laurdan (Invitrogen, San Diego,
CA) surfactant labeling (1% dye/phospholipid mol/mol) was carried out as
in Ravasio et al. (15). Cholesterol and taurocholic acid were obtained from
Avanti Lipids (Birmingham, AL) and Sigma (St. Louis, MO), respectively.
Complexes of cholesterol and methyl-b-cyclodextrine (MbCD) were
obtained commercially as Cholesterol Water Soluble from Sigma.Methods
Biochemical analysis of meconium
For all the analysis, meconium was prepared at a final concentration of
1 mg/mL. Total protein content was measured by the Lowry method (16)
and the total phospholipid content as described by Rouser et al. (14). Choles-
terol concentration was estimated using an enzymatic colorimetric method
commercially provided by Spinreact (Girona, Spain) and total bile acids
by an enzymatic colorimetric kit provided by Materlab (Madrid, Spain).
Surface balance measurements
P-t isotherms. Surfactant adsorption was measured over time in a Teflon
cup (Nima Technology, Coventry, UK) with 1.5 mL of stirred subphase at
25C, as described (17). One-hundred-fifty micrograms of surfactant were
injected into the subphase, that in some experiments contained meconium,
and pressure-time kinetics were followed over 5 min.
P-t spreading kinetics. Adsorption of native or meconium-pretreated
surfactant was also assessed after direct spreading at the interface of
a 22.5 cm2 trough (Nima Technology) containing 14 mL of subphase.
P-area isotherms. Native or meconium pretreated surfactant was spread
onto a buffered (5 mM Tris pH 7, 150 mM NaCl) subphase in a surface
balance equipped with a continuous Teflon ribbon barrier and a 200 cm2
trough (Nima Technology). After 10 min equilibration, the resulting films
were compressed at 60 cm2/min. Langmuir-Blodgett films were prepared
by transferring films onto glass coverslides using the COVASP method as
described elsewhere (18). Epifluorescence microscopy images were
obtained in an Axioplan II microscope (Zeiss, Dublin, CA) and analyzed
with Image J software.
Captive bubble surfactometer
Surfactant performance at 37C was evaluated by a modified captive bubble
surfactometer as described previously (19,20). The chamber contained 5mM
Tris-HCl pH7, 150mMNaCl, 10%sucrose,where a small air bubble (0.035–
0.040 cm3) was formed. Then, ~150 nL of surfactant (25mg/mL)was depos-
ited at the bubble surface by a transparent capillary. A 5-min adsorption (film
formation) period followed the introduction of surfactant into the chamber
during which the change in surface tension (g) was monitored from changes
in the shape of the bubble (21). The chamber was then sealed and the bubble
was rapidly (1 s) expanded to 0.15 cm3, to record postexpansion adsorption.
Five minutes after expansion, quasistatic cycles started. The bubble sizewasfirst reduced and then enlarged in a stepwise fashion. There was 1-min inter-
cycle delay between each of four quasistatic cycles and a further 1-min delay
before starting dynamic cycles, in which the bubblewas continuously varied
for 20 cycles at 20 cycles/min. Data from initial and postexpansion adsorp-
tion are presented as averages from three experiments and quasistatic and
dynamic cycles correspond to single representative experiments.
Fluorescence microplate assay
Accumulation of surfactant at the interface was evaluated in 96-well micro-
titer plates as described by Ravasio et al. (15), in a FLUORSTAR Optima
Microplate Reader (BMG Labtech, Offenburg, Germany). In these experi-
ments, meconium or meconium organic extract was mixed in 100 mL
subphase. Three micrograms of native surfactant was applied at the bottom
of each well, and the fluorescence intensity reaching the surface was
followed for 2 h at 25C. Data in these experiments are presented as the
average of three replicates with their standard deviation, in relative fluores-
cence units (RFU-bg) corrected by subtraction of the measured background.
Laurdan thermotropic profiles
Laurdan fluorescence emission spectra of surfactant suspensions were
obtained at different temperatures in a spectrofluorimeter SLM-Aminco
AB2 (Urbana, IL). Emission spectra were recorded at 400–540 nm upon
excitation at 370 nm. Laurdan emission is typically blue in the gel phase
and green at the liquid crystalline phase (22). Spectral changes were
analyzed using the generalized polarization (GP) function, defined as
GP ¼ ðIB  IRÞ=ðIB þ IRÞ;
with IB and IR being the intensities at the blue and red edges of the emission
spectrum, respectively (22,23).
Differential scanning calorimetry
Differential scanning calorimetry (DSC) thermograms of native surfactant
or surfactant suspensions preexposed to meconium or taurocholic acid
(TA) and cholesterol (Chol), were obtained in a model No. MC-2 microcal-
orimeter (MicroCal, Amherst, MA) (20). Surfactant concentration in these
experiments was 3 mg/mL, with or without the addition of 10 mg/mLmeco-
nium, or TA (10 mM)þ 1.6% Cholesterol (w/w, Chol/phospholipid) against
5 mM Tris buffer 150 mM NaCl as a reference. Scans were obtained from
15 to 55C, at 30C/h. Data were analyzed with the software Origin (Origin
Labs, Northampton, MA). Thermodynamic parameters were obtained from
DSC scans of three independent batches of native surfactant.
Data reproducibility
When possible, the figures represent the mean 5 SD after averaging data
from 3–6 independent experiments, using at least two, and often three,
different batches of surfactant. The behavior of different surfactant batches
was consistent in the experiments.RESULTS
Interfacial adsorption
Native surfactant adsorbs in a few seconds from the subphase
into the interface, rapidly reaching equilibrium surface pres-
sures (peq) of ~45 mN/m (Fig. 1 A). Increasing concentra-
tions of meconium produce a progressive reduction of
interfacial adsorption, which keeps being fast at first
instance, but reaches progressively lower equilibrium pres-
sures at longer term. The inset in Fig. 1 A plots the maximum
pressure reached during the time of the experiment versus the
concentration of meconium into the subphase. The lowestBiophysical Journal 100(3) 646–655
FIGURE 1 Interfacial adsorption of native surfactant exposed to different
concentrations of meconium. (A) Interfacial adsorption of surfactant upon
injection into the subphase of a Wilhelmy balance containing the indicated
concentrations of meconium (mg/mL). (Inset) Surface pressure reached by
the absorbed material at 100 s after injection versus the concentration of
meconium. (B) Interfacial adsorptionof surfactant preincubatedwith the indi-
cated concentrations of meconium (mg/mL) once spread directly at the air-
water interface of a surface balance. (Inset) Surface pressure reached by the
spread material 100 s after spreading versus the concentration of meconium.
FIGURE 2 Compression isotherms of surfactant and meconium. (A)
Low-pressure (right panel) and high-pressure (left panel) segments of the
compression isotherm of films formed by native pulmonary surfactant
without (solid line) or with (short dashed line) preexposure to meconium,
once spread at the air-water interface. (B) Full compression-expansion
cycling isotherms of films formed by meconium-free (solid line) or meco-
nium-treated (dashed line) surfactant. (C) Compression isotherm of a film
formed by spreading of meconium at the air-water interface.
648 Lopez-Rodriguez et al.meconium concentrations tested already produce a substan-
tial decrease in the adsorption of surfactant.
Adsorption of surfactant complexes from the subphase
involves two processes: movement of surfactant particles
through the bulk aqueous phase to reach subsurface compart-
ments and transfer of surface active molecules from surface
attached structures into the interface. To discriminate the
effect of meconium in these two processes, we analyzed
the effect of meconium exposure on the ability of surfactant
to adsorb and spread after direct deposition at the interface.
Fig. 1 B compares spreading kinetics of native surfactant
onto a meconium-free subphase and onto subphases contain-
ing increasing concentrations of meconium. Exposure to
progressively higher meconium concentrations also reduces
the ability of surfactant to spread and adsorb at the interface,
but to a much lesser extent than observed when injecting the
surfactant sample into the bulk subphase.Compression isotherms
Fig. 2 A compares the compression isotherms obtained from
films formed by interfacial spreading of native surfactant orBiophysical Journal 100(3) 646–655from native surfactant pretreated with meconium
(10 mg/mL). Typical isotherms from native surfactant
show increasing surface pressure as a function of area reduc-
tion from a variable lift-off molecular area—the area at
which surface pressure starts to rise—up to reaching
a plateau at ~45 mN/m.
Differences in apparent molecular areas of the surfactant
isotherms are due to minor, uncontrollable, differences from
FIGURE 3 Effect of meconium on the surface activity of surfactant as
evaluated in a captive bubble surfactometer. (A) Initial and postexpansion
Inhibition of Surfactant by Meconium 649sample to sample in the efficiency of transfer of spread
surfactant into the interface. Compression beyond the
plateau causes a sharp increase in pressure up to reach
a collapse pressure of 70 mN/m. The isotherm from meco-
nium pretreated surfactant differs. At low surface pressures,
the isotherm exhibits an expansion to larger areas, meaning
that the material transferred into the interface occupies
a larger space than that taken by surfactant mixtures without
meconium. However, meconium-treated surfactant requires
a greater degree of compression to reach and maintain high
surface pressures compared with meconium-free surfactant.
These data are consistent with meconium constituents in-
serting into surfactant and expanding the isotherm at low
compression. This material from meconium may well
have low collapse pressures and hence is desorbed from
the interface at high pressures. The data also suggest that
at high compression rates, desorption of meconium products
may also remove some of the surfactant phospholipids.
Results in Fig. 2 B, obtained either frommeconium-free or
meconium-treated surfactant films, show that the expansion
isotherm of meconium pretreated surfactant yields lower
area/pressures, likely as a consequence of the irreversible
loss of part of the material (surfactant þ meconium) during
compression. Fig. 2 C shows the compression isotherm of
pure meconium, spread at the air-liquid interface. The
collapse pressure of meconium film is 25 mN/m, indicating
that most of its components are squeezed-out from the inter-
face at pressures above that threshold. Interestingly, meco-
nium isotherms exhibit segments with clearly distinct
slopes, which may indicate the coexistence of components
with different interfacial stability.adsorption of native surfactant in the absence (solid circles) or in the pres-
ence (open circles) of 10 mg/mL meconium (representing 1.6% Chol w/w)
(B) Quasistatic (Q-static, upper panels) and dynamic (lower panels)
compression-expansion isotherms of surfactant films formed in the absence
(left panels) or in the presence (right panels) of meconium; plotted are
isotherms obtained from cycle 1 (solid), 2 (open), 3 (shaded), and 4 (half
solid) for the quasistatic and 1 (solid), 10 (open), and 20 (shaded) for the
dynamic cycling.Captive bubble surfactometry
This technique better simulates the compression-expansion
cycling that occurs at the breathing interface (8,19,21).
Fig. 3 A compares interfacial adsorption kinetics of native
surfactant and surfactant preexposed to meconium, as
assessed after deposition at the interface of the captive air
bubble in the captive bubble surfactometer. NS adsorbs to
form a stable surface film with a minimum equilibrium
surface tension of ~23 mN/m within the first second after
deposition. Pretreated surfactant adsorbs initially almost as
fast as nontreated surfactant, but to a higher equilibrium
tension of 25 mN/m. However, readsorption of excess
material upon expansion of the bubble (see right panel in
Fig. 3 A) occurs identically in meconium-treated and non-
treated surfactant.
Cycling isotherms obtained from native surfactant films
show practically no compression/expansion hysteresis along
the successive quasistatic or dynamic cycles (Fig. 3 B). Only
the first quasistatic cycle exhibits a marginal hysteresis,
which is lost in the subsequent cycles. Native surfactant
isotherms reach surface tensions %2 mN/m with <20%
compression (see summary of data in Table S1 in the Sup-porting Material). In contrast, isotherms of meconium-
treated surfactant films exhibit a considerable hysteresis.
Under quasistatic conditions, both compression and expan-
sion isotherms show marked plateaus at the equilibrium
pressure, which are progressively reduced in the subsequent
cycles.
These plateaus practically disappear upon dynamic
cycling, likely due to completion of film depuration, i.e.,
once rapid cycling to the highest pressures promotes the
squeeze-out and the subsequent desorption of the compo-
nents inserted from meconium into the surfactant films.
However, complete refining of the isotherms requires
much larger compression ratios (~50%) than required by
meconium-free surfactant. Meconium addition does not
increase the maximum surface tensions, reached upon
expansion, again confirming that meconium does not impairBiophysical Journal 100(3) 646–655
FIGURE 4 Effect of meconium on the structure
of surfactant films. (A) Epifluorescence micros-
copy images from interfacial films of native surfac-
tant containing a trace of the fluorescent probe
BODIPY-PC, in the absence (left pictures) or in
the presence (right pictures) of meconium,
obtained upon transfer to glass at the indicated
surface pressures. Graphs on the right correspond
to the quantitative analysis of the density of
condensed domains (B), their average size (C),
and the total area occupied by the condensed phase
(D) versus the surface pressure, for meconium-free
(solid bars) and meconium-treated (shaded bars)
surfactant films.
650 Lopez-Rodriguez et al.the respreading potential of surfactant that is already associ-
ated with the interface.
Structure of the surface film
Evidence suggests that meconium incorporates constituent
molecules into surfactant films and that meconium-treated
surfactant films require compression-driven depuration
before becoming competent to reach the lowest tensions.
This finding may indicate that meconium also affects the
structure of surfactant films. Under epifluorescence micros-
copy, the lateral structure of native surfactant films subjected
to compression, exhibits features that have been well charac-
terized (25,26) (Fig. 4 A). At pressures higher than 10 mN/m
there is a progressive segregation of small condensed
domains, which grow with compression to reach maximum
size at ~30 mN/m and then decrease upon higher compres-
sion (see quantitation of domain morphologies in Fig. 4, B–
D).Dark condensed domains always showed a rounded shape
and were homogeneously distributed, as dispersed in the
fluorescent, presumably liquid-disordered, film matrix.
In contrast, morphology of films from meconium-treated
surfactant was different. Overall, meconium surfactant
mixtures showed higher proportions of condensedlike phase
at any pressure. This could be related with a condensing
effect caused by the components inserted into surfactant
by meconium. Also in contrast to natural surfactant films,
condensed domains showed a strong tendency to aggregate
in meconium-exposed layers, producing a relatively hetero-
geneous morphology in these films. Segregation of largeBiophysical Journal 100(3) 646–655clusters of condensed phase from large areas devoid of
condensed domains could be an important source of insta-
bility for the films as a whole. Meconium-treated films
also showed the presence of numerous bright spots, likely
corresponding to material that has been already squeezed-
out from the interface during compression due to its low
interfacial stability.Biochemical analysis of meconium
Table S2 summarizes the amounts of total protein, phospho-
lipids, cholesterol, and bile acids in meconium. Still, most of
meconium weight seems to consist of nondetermined
components, possibly salts, heme byproducts, and others.
Particularly remarkable is the presence of a substantial
amount of cholesterol and bile acids, which may perturb
the structure and function of surfactant. We have therefore
compared the effect of meconium with a mixture of choles-
terol and taurocholic acid (Chol/TA). TA was used because
it is one of the most abundant human bile acids (27).Accumulation of surfactant at the interface
A method recently developed allows evaluation of the
amount of surfactant material accumulating at the interface
(15). We therefore tested whether meconium and Chol/TA
produced similar alteration in the ability of surfactant to
form surface films. Fig. 5 A shows how native surfactant
rapidly reaches the interface and stably remains associated
FIGURE 5 Effect of meconium on the interfacial accumulation of surfac-
tant. (A) Accumulation of material into the interface upon adsorption of
fluorescently labeled native surfactant in the presence of the indicated
concentrations of meconium in mg/mL (top), of the organic extract (OE)
from meconium (center) or of a mixture of taurocholic acid and cholesterol
(TA/Chol, bottom), all of them expressed as mg/mL of cholesterol added.
(B) Relative accumulation of labeled surfactant into the interface as a func-
tion of the amount of meconium (solid), meconium organic extract (open),
or TA þ cholesterol (shaded), 10 min (left panel) or 60 min (right panel)
after injection of surfactant into the subphase. Lines are mere guides to
eye, illustrating the similar trends of the three types of samples.
FIGURE 6 Effect of cholesterol-mobilizing complexes on the surface
activity of surfactant as evaluated in a captive bubble surfactometer. (A)
Initial and postexpansion adsorption of native surfactant in the presence
of a mixture of TA and cholesterol (1.6% Cholesterol w/w) (solid circles)
or in the presence of complexes of cholesterol and MbCD (open circles)
representing a final proportion of cholesterol of 1.6% w/w. (B) Quasistatic
(Q-static, upper panels) and dynamic (lower panels) compression-expan-
sion isotherms of surfactant films formed in the presence of Chol/TA (left
panels) or Chol/MbCD (right panels) complexes; plotted are isotherms ob-
tained from cycle 1 (solid), 2 (open), 3 (shaded), and 4 (half solid) for the
quasistatic and 1 (solid), 10 (open), and 20 (shaded) for the dynamic
cycling.
Inhibition of Surfactant by Meconium 651with it, whereas its exposure to increasing concentrations of
meconium produces a progressive reduction in the amount
of interfacial surfactant.
A similar inhibiting effect was observed when native
surfactant was exposed to a suspension prepared from
a chloroform/methanol extract of meconium (see Fig. 5 A,
middle panel), indicating that the inhibiting compounds
are extractable by organic solvents. The lower panel in
Fig. 5 A shows how the inhibition profile of surfactant by
meconium can be fully mimicked by exposure of surfactant
to a mixture Chol/TA containing quantities of cholesterolcomparable to those found in meconium. Fig. 5 B illustrates
that the concentration dependence of surfactant inhibition
by meconium is matched by meconium organic extract or
the Chol/TA mixture, particularly at long term, when the
maximal amount of surface-associated material is reached.
The larger differences observed at short times likely high-
light the different kinetics of inhibition once surfactant is
exposed to the three substances. Meconium could be the
slowest inhibiting substance due to its complexity.Mimicking of meconium inhibition by cholesterol
mobilizing complexes
Fig. 6 shows that exposure of surfactant to Chol/TA has
similar inhibiting effects as meconium. The mixtureBiophysical Journal 100(3) 646–655
FIGURE 7 Effect of meconium on the thermotropic properties of surfac-
tant membranes. (A) Thermotropic profiles of generalized polarization (GP)
652 Lopez-Rodriguez et al.Chol/TA reduces only slightly the initial adsorption rate of
surfactant with no effect in adsorption postexpansion.
Compression-expansion isotherms of Chol/TA-treated
surfactant were, however, substantially affected, in a manner
entirely comparable to the effect of meconium (compare
Fig. 6 with Fig. 3). Much larger compression was required
for surfactant to reach the minimal tensions if preexposed
to Chol/TA, particularly during the quasistatic regime. The
hysteresis of the isotherms was progressively reduced
during the subsequent cycles presumably as a result of the
progressive depuration of spurious components. Exposure
to Chol/TA combinations did not increase the maximal
surface tension, as occurred upon exposure to meconium.
In some experiments, we preincubated surfactant with
dried cholesterol films, prepared by evaporation of organic
solutions of cholesterol and, in contrast to the effect of
Chol/TA mixtures, we did not detect significant effects on
surfactant surface activity (not shown). This suggests
a potential role of bile acids as cholesterol mobilizing agents
to facilitate transference of cholesterol into surfactant
complexes and so to mediate inhibition. Fig. 6 shows how
the exposure of surfactant to the combination of cholesterol
with another well-known steroid-mobilizing agent, methyl-
b-cyclodextrin, produces perturbations on surfactant surface
activity that are practically indistinguishable from those
induced by meconium or Chol/TA complexes.fluorescence obtained from the fluorescence spectra of Laurdan-labeled
native surfactant (solid) or surfactant preexposed to meconium (open), or
to TAþ cholesterol (shaded). (B) DSC thermograms from native surfactant
(solid line) or surfactant preexposed to meconium (long dashed line) or to
TA þ cholesterol (short dashed line).Thermotropic profiles of surfactant membranes
Laurdan is a fluorescent probe sensitive to the level of
hydration of the headgroup region of phospholipid
membranes, which depends on lipid packing and membrane
phase (28). The thermotropic profile of the fluorescence of
a Laurdan trace incorporated into native surfactant
membranes provides information on the effect of tempera-
ture on surfactant structure. Fig. 7 A shows that native
surfactant membranes manifest a broad transition from
ordered, relatively dehydrated states at low temperatures
to more disordered and loosely packed configurations at
high temperatures, with a melting temperature (calculated
as the temperature at which Laurdan GP is halfway from
that of ordered to that of disordered membranes) of ~35C.
Fluorescence of Laurdan inserted into surfactant treated
withmeconium indicates that thesemembranes have become
more hydrated/disordered at low temperatures and more
ordered/dehydrated at high temperatures than the
membranes that were not exposed to meconium. A practi-
cally identical broadening of the thermotropic transition of
surfactant membranes was observed upon exposure of
surfactant to the Chol/TA mixture. On the other hand, if
only taurocholic acid was used as surfactant perturbing
compound, the thermotropic profile of surfactant membranes
was only affected at low temperatures, where the bile acid
seems to produce an apparent disordering effect over the
surfactant membrane ordered states (data not shown).Biophysical Journal 100(3) 646–655To confirm the nature of the perturbations introduced by
meconium into surfactant membranes, we compared differ-
ential scanning calorimetry thermograms of native surfac-
tant and surfactant treated with meconium or the Chol/TA
mixture. Natural surfactant shows a complex and broad
calorimetric peak between 15 and 40C with a Tm of
~35C (Fig. 7 B) as it has been reported before (29). The
thermogram from surfactant exposed to meconium exhibits
also a similarly broaden thermotropic peak, but with
a substantially reduced associated enthalpy (calculated as
the area under the peak, see summary of calorimetric param-
eters in Table S3). The thermotropic behavior of surfactant
treated with the Chol/TA mixture reproduces that of meco-
nium-treated surfactant, including a similar reduction of
enthalpy. The reduction in enthalpy caused by the combined
action of cholesterol and the bile acid therefore parallels the
decrease in the amplitude of the thermotropic transition as
reported by Laurdan.DISCUSSION
In the past, inhibition by meconium had been found with
clinical surfactants such as Curosurf (27), Surfactant-TA
Inhibition of Surfactant by Meconium 653(30–32), or others (33), but no data were available on the
inhibition of natural pulmonary surfactant by meconium,
a process actually occurring with MAS. The data presented
here support that the inhibitory action of meconium is
mediated by a direct incorporation of meconium compo-
nents into surfactant membranes and films and their subse-
quent perturbation. The nature of the perturbations
observed are compatible with cholesterol being an important
inhibitory element that alters the properties of surfactant
membranes and films in defined and recognizable ways.
The inhibitory action of the presence of excess choles-
terol in surfactant complexes has been widely reported
and largely studied. The early finding that cholesterol was
deleterious for surfactant function, at least as assessed
in vitro, led to the removal of cholesterol from most of the
surfactant preparations currently used for the treatment of
respiratory pathologies (34). Recent studies have also
reported that excess of cholesterol could be also a pathogenic
factor in ARDS (35). How much cholesterol is essential as
a constituent of pulmonary surfactant is under much discus-
sion in recent reports, as a minimal amount of cholesterol is
required for natural pulmonary surfactant membranes to
adopt their characteristic lateral structure (36) and proper
dynamics (29). Therefore the amount of cholesterol in
surfactant must be carefully regulated to maintain the
proportions that optimize surfactant performance whereas
excessive cholesterol has deleterious consequences (8).
Moreover, regulation of the amount of cholesterol in surfac-
tant may be a physiological adaptive response to certain
environmental changes (37).
Our findings indicate that the effect of cholesterol con-
tained in meconium as an inhibitor of surfactant, could be
mediated by the bile acids in this material. Cholesterol alone
failed to reproduce the effects caused by meconium (not
shown), probably because the low solubility of cholesterol
in aqueous medium prevent its extensive transfer into
surfactant complexes. Bile acids may act to enable insertion
of cholesterol into surfactant membranes resulting in surfac-
tant dysfunction as occur upon exposure to complexes of
methyl-b-cyclodextrine and cholesterol. Inhibition by
meconium could therefore constitute a particular case of
inhibition by excess cholesterol facilitated by the presence
of bile salts as cholesterol-mobilizing agent.
Facilitated transfer of cholesterol could be also a signifi-
cant contribution in other pathological alterations of surfac-
tant such as in the increase of neutral lipids associated with
surfactant inhibition in patients with ARDS (35). The
increase of cholesterol in surfactant as a consequence of
serum leakage into airspaces could be dependent on the
cholesterol-mobilizing properties of lipoproteins. The
notion of the effect of cholesterol-mobilizing agents on
structure and activity of pulmonary surfactant is also behind
the idea proposed by Gunasekara et al. (38) that cyclodex-
trine could be used as an additive in therapeutic surfactants,
where it could aid to deplete the excess of cholesterol fromendogenous inhibited surfactant. Our results suggest that
incorporation of cholesterol-mobilizing agents such as cy-
clodextrine into exogenous surfactants might even have
the opposite, negative, effect and promote further inhibition
if more extensive mobilization of cholesterol occurs.
An effective surfactant must optimize three main proper-
ties: rapid interfacial adsorption, very low surface tension
upon film compression, and efficient film replenishment
upon expansion (9,39). Meconium alters these three proper-
ties, impairing surfactant performance. It reduces substan-
tially accumulation of surfactant at the interface. Perhaps
some of the elements incorporated by meconium into
surfactant are directly altering the molecular structures
responsible for their attachment to the interface.
Meconium itself has a relatively low interfacial collapse
pressure, suggesting that it desorbs easily from the interface.
Perhaps the accumulation of meconium components into
surfactant membranes may also lead to a facilitated desorp-
tion, which reduces the amounts of surfactant accumulated
at the interface. The detergent properties of bile acids may
be responsible for facilitated desorption of surfactant
complexes from the interface. The effects of bile acids as
a single inhibitory component had been previously studied
with a clinical surfactant, Curosurf (27). This study identi-
fied some similarities between taurocholic acid and meco-
nium, but in this study, taurocholic acid by itself did not
reproduce all the effects observed after exposure of surfac-
tant to meconium.
The alteration of the structure of surfactant as a conse-
quence of the exposure to meconium, could explain the
altered ability of meconium-treated surfactant to reach
very low surface tensions upon compression. Bile acid-
promoted incorporation of cholesterol into surfactant could
be responsible of the partial fluidization of the condensed
states of membranes and films and the requirement of
much larger compression to depurate surface films before
reaching the lowest tensions. Our experiments in the captive
bubble surfactometer indicate that during compression-
expansion cycling, surface films may lose deleterious
components of meconium, but this could depend on the total
amount of material incorporated. It is particularly intriguing
that meconium increases the fraction of surface films occu-
pied by condensed domains as observed by epifluorescence
microscopy, especially considering that meconium seems to
fluidize/decrease packing in surfactant membranes. We
speculate that incorporation of cholesterol, and perhaps
bile salts, into the condensed domains would increase their
fractional area while decreasing their internal molecular
packing. This would also explain the reduction of melting
enthalpy of surfactant membranes that had been exposed
to meconium. An altered composition of condensed surfac-
tant domains could be responsible for their abnormal
propensity to cluster, which, in turn, could have conse-
quences on the lack of stability of meconium contaminated
films.Biophysical Journal 100(3) 646–655
654 Lopez-Rodriguez et al.The nature of the inhibitory mechanisms of meconium re-
vealed here suggests strategies to improve the surfactant
treatment of several lung diseases. In the case of meconium
aspiration pneumonia, the use of surfactant preparations free
of cholesterol would appear logical based on our in vitro
results. A cholesterol-free preparation might resist meco-
nium inhibition to a greater degree than a cholesterol-con-
taining surfactant. However, a complete lack of
cholesterol may adversely affect the beneficial effects
offered by physiological amounts of cholesterol. Supple-
menting clinical surfactants with antagonists of bile acids
is an alternative approach. Ursodeoxicholic acid, for
instance, is a hydrophilic bile acid which has been proposed
as a membrane-protective agent useful in the treatment of
cholestasis (40). Similar strategies may be useful in
ARDS wherein increased amounts of cholesterol have
been found with surfactant obtained from these patients
(35). Targeting of surfactant inhibitors by adding specific
inhibitor antagonists to therapeutic surfactants may improve
clinical responses in patients with surfactant dysfunction
who heretofore have not responded well to conventional
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